ADC Therapeutics CONFRONTING CANCER WITH THE FULL POTENTIAL OF OUR SCIENCE

We are confronting cancer with the full potential of our science to bring unique, targeted therapies and hope to patients and their families.

ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.

OUR MISSION

OUR COMPANY

We will transform what patients and their families can expect from cancer therapy. By achieving our mission and living our core values, we look forward to seeing our vision become a reality.

OUR VISION FOR THE FUTURE

“At ADC Therapeutics, we believe that science evolves by building

and improving on previous discoveries. The progress we’ve

seen in antibody drug conjugates over the past several years is

evidence of this. Now by advancing next-generation ADCs with

PBD dimer technology, we’re seeing the potential for significant

clinical activity in patients with cancer, even those who are often

overlooked or who have few therapeutic options. This technology

will change the future of patient care, but one thing that will

remain the same is our belief that serving those in need is not

just a priority. It’s a privilege.”

WELCOME TO ADC THERAPEUTICS

CHRIS MARTIN CHIEF EXECUTIVE OFFICER, CO-FOUNDER AND DIRECTOR, ADC THERAPEUTICS

AN MOA THAT FEATURES THE STEALTH-LIKE PROPERTIES OF PBD DIMER TOXINS• The antigen-targeted antibody binds to a specific tumor cell surface

antigen and internalizes the drug conjugate

• The potent PBD dimer is released inside the cell, where it then creates a covalent cross-link between the strands of the DNA double helix

• Because these cross links do not trigger DNA repair, they are invisible to repair mechanisms and can covertly persist to interrupt cell division

“Lonca has the potential to fulfill a critical unmet need for a new therapy and become a key part of the treatment paradigm for patients with relapsed/refractory DLBCL.”

ADC Therapeutics is advancing next-generation ADCs with highly potent and targeted PBD dimer technology. These proprietary PBD-based ADCs are expected to provide a novel way to treat hematological cancers and solid tumors, address significant unmet medical needs, and improve the lives of patients with cancer.

JAY FEINGOLD, MD, PhD SVP AND CHIEF MEDICAL OFFICER

DELIVERING ON THE PROMISE OF SCIENCE BY ADVANCING NEXT-GENERATION PBD-BASED ADCs

G PuPy AC T

GPu PyA CT

N

NH

H

H

H

H

H

N

NN

N

O

OO

OOMe

OMeCH2 CHCH

5’

3’

Formation of cytotoxic DNA interstrand cross-linksBindingTarget

Uptake

Teserine released

DNA cross-linking

Apoptosis

ADC Lysosomal uptake Antibody degradation

22

“PBDs cross link in the DNA of cancer cells, enabling them to elude DNA repair/cancer resistance mechanisms. This allows for a longer lasting effect on cancer cells.”

PATRICK VAN BERKEL, PhD SVP, RESEARCH AND DEVELOPMENT

DLBCL: Diffuse Large B-cell Lymphoma.

In clinical trials, Lonca has demonstrated significant single-agent clinical activity across a broad population of patients with relapsed or refractory diffuse large B-cell, mantle cell, and follicular lymphomas. Lead candidate Lonca is being evaluated in a pivotal phase 2 study in patients with relapsed or refractory DLBCL and ADCT intends to commence a phase 3 randomized study of Lonca in combination with rituximab versus immunochemotherapy.

THE LOTIS CLINICAL DEVELOPMENT PROGRAM

Lonca is the focus and PBD-based technology is the foundation for the LOTIS Clinical Development Program. Lonca is advancing in clinical trials and demonstrating significant clinical activity across multiple indications.

LEAD CANDIDATES LONCASTUXIMAB TESIRINE (Lonca)

A DIVERSIFIED PIPELINE OF ADCs FOR THE TREATMENT OF HEMATOLOGICAL CANCERS AND SOLID TUMORS

Preclinical

Loncastuximab Tesirine (ADCT-402, Lonca)Targeting CD19

Diffuse Large B-Cell LymphomaFollicular Lymphoma

Diffuse Large B-Cell Lymphoma and Mantle CellLymphoma, in combination with ibrutinib

Hodgkin LymphomaNon-Hodgkin Lymphoma

Acute Lymphoblastic Leukemia

Various Solid Tumors

Various Solid Tumors

Various Solid Tumors

Various Solid Tumors

Camidanlumab Tesirine (ADCT-301, Cami)Targeting CD25

Pivotal

Pivotal

ADCT-602Targeting CD22

Camidanlumab Tesirine (ADCT-301, Cami)Targeting CD25

ADCT-601Targeting AXL

ADCT-901Targeting KAAG1

ADCT-701Targeting DLK1

Phase 1a Phase 1b Phase 2 Phase 3/Confirmatory Rights

Hem

atol

ogy

Fran

chis

eSo

lid T

umor

Fra

nchi

se

GENMAB

GENMAB

Cami is ADCT’s second lead candidate. It has demonstrated significant clinical activity in heavily pretreated patients with Hodgkin lymphoma. Based on its mechanism targeting CD25/regulatory T cells, Cami is also demonstrating potential in the treatment of solid tumors.

CAMIDANLUMAB TESIRINE (Cami)

ADC Therapeutics MOVING SCIENCE FORWARD

ADC Therapeutics Head Office | Route de la Corniche 3B, 1066 Epalinges, SwitzerlandADC Therapeutics America |430 Mountain Avenue, Suite #404. New Providence, NJ 07974, USA.

©2020 ADC Therapeutics. All rights reserved.

ADCTherapeutics.comFor information about the LOTIS Clinical Development Program, email ADC Therapeutics at medicalinformation@ADCTherapeutics.com.

Loncastuximab tesirine (ADCT-402) and camidanlumab tesirine (ADCT-301) are investigational agents, and safety and efficacy have not yet been established.